{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.743","value":"73.18"},{"groupId":"OG001","spread":"16.534","value":"53.95"},{"groupId":"OG002","spread":"17.199","value":"74.80"}]}],"title":"Baseline, n=5, 5, 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.131","value":"82.84"},{"groupId":"OG001","spread":"13.664","value":"61.57"},{"groupId":"OG002","spread":"14.798","value":"71.54"}]}],"title":"Week 6, n=4, 5, 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.712","value":"84.14"},{"groupId":"OG001","spread":"12.349","value":"66.43"},{"groupId":"OG002","spread":"17.887","value":"65.58"}]}],"title":"Week 12, n=4, 4, 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.228","value":"76.38"},{"groupId":"OG001","spread":"15.995","value":"82.50"},{"groupId":"OG002","spread":"12.056","value":"78.87"}]}],"title":"Week 24, n= 3, 4, 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"description":"The KIT questionnaire measures the impact on the quality of life determined by the participant and the guardian by self reported outcomes at Baseline or the Screening Visit, after 6 weeks of treatment, after 12 weeks of treatment and at the end of treatment or withdrawal from the study. The KIT total score is calculated from the scores of each of the individual questions from Q1 - Q26 (excluding any answer that is 'Not applicable'). The code list used for the individual question scores is: 1 = never, 2 = seldom, 3 = sometimes, 4 = often, 5 = always and 9 = not applicable. The range of values the total score can take is 0 (worst) to 100 (best). For subjects under the age of six, the family questionnaire (parental proxy) has been used.","dispersionType":"Standard Deviation","groups":[{"description":"Participants aged between 12 and 17 years received a 24-week Open-label treatment of eltrombopag administered as a tablet. The starting dose of eltrombopag was 25 milligrams (mg), once daily (QD). The participants of East Asian ancestry began at 12.5mg QD. The maximum dose allowed was 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.","id":"OG000","title":"Part 1 (Dose-Finding Period) Cohort 1"},{"description":"Participants aged between 6 and 11 years received a 24-week Open-Label treatment of eltrombopag administered as a tablet. The starting dose of eltrombopag was based on the body weight. Participants with a weight of \\<27 kilograms (kg) received 12.5 mg QD (approximately 0.5 - 0.7 mg/kg QD) and participants with a weight of \\>=27 kg received 25 mg QD (approximately 0.5 - 0.8 mg/kg QD). The maximum dose allowed was 2 mg/kg and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.","id":"OG001","title":"Part 1 (Dose-Finding Period) Cohort 2"},{"description":"Participants aged between 1 and 5 years received a 24-week Open-Label treatment of eltrombopag administered as a dry powder for oral suspension. The starting dose of eltrombopag was 0.7 mg/kg QD. Participants of East Asian ancestry began at 0.5 mg/kg/day. The maximum dose allowed was 2 mg/kg, and could not exceed 75 mg daily. All participants enrolled in the study underwent individual dose titration based upon platelet response.","id":"OG002","title":"Part 1 (Dose-Finding Period) Cohort 3"}],"paramType":"MEAN","populationDescription":"ITT Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the ITT Population.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 6, Week 12, and Week 24 of Part 1","title":"Kids' ITP Tool (KIT) Questionnaire Total Score at Baseline, Week 6, Week 12, and Week 24 as Assessed Using the KIT Questionnaire During the Dose Finding Period, Part 1","type":"SECONDARY","unitOfMeasure":"Score on scale"}